Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.
Market Analysis and Insights: Global Nonalcoholic Steatohepatitis (NASH) Market
The global Nonalcoholic Steatohepatitis (NASH) market size is projected to reach US$ 46230 million by 2028, from US$ 3064.2 million in 2021, at a CAGR of 46.7% during 2022-2028.
NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Nonalcoholic Steatohepatitis (NASH) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Nonalcoholic Steatohepatitis (NASH) market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Nonalcoholic Steatohepatitis (NASH) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Nonalcoholic Steatohepatitis (NASH) market.
Global Nonalcoholic Steatohepatitis (NASH) Scope and Market Size
Nonalcoholic Steatohepatitis (NASH) market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Nonalcoholic Steatohepatitis (NASH) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
- Obeticholic acid(OCA)
- Selonsertib
Segment by Application
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
By Company
- AstraZeneca
- Arena Pharmaceuticals
- GSK
- Novo Nordisk
- Roche
- Vivus
- Arisaph Pharmaceuticals
- Cempra Pharmaceuticals
- Galectin Therapeutics
- Galmed Pharmaceuticals
- Genfit
- Gilead
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
TABLE OF CONTENTS
1 Report Business Overview
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
- 1.2.2 Obeticholic acid(OCA)
- 1.2.3 Selonsertib
- 1.3 Market by Application
- 1.3.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
- 1.3.2 Hospital Pharmacy
- 1.3.3 Online Provider
- 1.3.4 Retail Pharmacy
- 1.4 Study Objectives
- 1.5 Years Considered
2 Global Growth Trends
- 2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Perspective (2017-2028)
- 2.2 Nonalcoholic Steatohepatitis (NASH) Growth Trends by Region
- 2.2.1 Nonalcoholic Steatohepatitis (NASH) Market Size by Region: 2017 VS 2021 VS 2028
- 2.2.2 Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Region (2017-2022)
- 2.2.3 Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Region (2023-2028)
- 2.3 Nonalcoholic Steatohepatitis (NASH) Market Dynamics
- 2.3.1 Nonalcoholic Steatohepatitis (NASH) Industry Trends
- 2.3.2 Nonalcoholic Steatohepatitis (NASH) Market Drivers
- 2.3.3 Nonalcoholic Steatohepatitis (NASH) Market Challenges
- 2.3.4 Nonalcoholic Steatohepatitis (NASH) Market Restraints
3 Competition Landscape by Key Players
- 3.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue
- 3.1.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue (2017-2022)
- 3.1.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Players (2017-2022)
- 3.2 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Players Covered: Ranking by Nonalcoholic Steatohepatitis (NASH) Revenue
- 3.4 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio
- 3.4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by Nonalcoholic Steatohepatitis (NASH) Revenue in 2021
- 3.5 Nonalcoholic Steatohepatitis (NASH) Key Players Head office and Area Served
- 3.6 Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
- 3.7 Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
- 3.8 Mergers & Acquisitions, Expansion Plans
4 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Type
- 4.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Type (2017-2022)
- 4.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2023-2028)
5 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Application
- 5.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Application (2017-2022)
- 5.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2023-2028)
6 North America
- 6.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
- 6.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type
- 6.2.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022)
- 6.2.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028)
- 6.2.3 North America Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2017-2028)
- 6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application
- 6.3.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022)
- 6.3.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028)
- 6.3.3 North America Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2017-2028)
- 6.4 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
- 6.4.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
- 6.4.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
- 6.4.3 U.S.
- 6.4.4 Canada
7 Europe
- 7.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
- 7.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type
- 7.2.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022)
- 7.2.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028)
- 7.2.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2017-2028)
- 7.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application
- 7.3.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022)
- 7.3.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028)
- 7.3.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2017-2028)
- 7.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country
- 7.4.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
- 7.4.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
- 7.4.3 Germany
- 7.4.4 France
- 7.4.5 U.K.
- 7.4.6 Italy
- 7.4.7 Russia
- 7.4.8 Nordic Countries
8 Asia-Pacific
- 8.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
- 8.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type
- 8.2.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022)
- 8.2.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028)
- 8.2.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2017-2028)
- 8.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application
- 8.3.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022)
- 8.3.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028)
- 8.3.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2017-2028)
- 8.4 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region
- 8.4.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2017-2022)
- 8.4.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2023-2028)
- 8.4.3 China
- 8.4.4 Japan
- 8.4.5 South Korea
- 8.4.6 Southeast Asia
- 8.4.7 India
- 8.4.8 Australia
9 Latin America
- 9.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
- 9.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type
- 9.2.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022)
- 9.2.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028)
- 9.2.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2017-2028)
- 9.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application
- 9.3.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022)
- 9.3.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028)
- 9.3.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2017-2028)
- 9.4 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
- 9.4.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
- 9.4.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
- 9.4.3 Mexico
- 9.4.4 Brazil
10 Middle East & Africa
- 10.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
- 10.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type
- 10.2.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022)
- 10.2.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028)
- 10.2.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2017-2028)
- 10.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application
- 10.3.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022)
- 10.3.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028)
- 10.3.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2017-2028)
- 10.4 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country
- 10.4.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
- 10.4.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
- 10.4.3 Turkey
- 10.4.4 Saudi Arabia
- 10.4.5 UAE
11 Key Players Profiles
- 11.1 AstraZeneca
- 11.1.1 AstraZeneca Company Details
- 11.1.2 AstraZeneca Business Overview
- 11.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Introduction
- 11.1.4 AstraZeneca Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
- 11.1.5 AstraZeneca Recent Developments
- 11.2 Arena Pharmaceuticals
- 11.2.1 Arena Pharmaceuticals Company Details
- 11.2.2 Arena Pharmaceuticals Business Overview
- 11.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
- 11.2.4 Arena Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
- 11.2.5 Arena Pharmaceuticals Recent Developments
- 11.3 GSK
- 11.3.1 GSK Company Details
- 11.3.2 GSK Business Overview
- 11.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Introduction
- 11.3.4 GSK Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
- 11.3.5 GSK Recent Developments
- 11.4 Novo Nordisk
- 11.4.1 Novo Nordisk Company Details
- 11.4.2 Novo Nordisk Business Overview
- 11.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Introduction
- 11.4.4 Novo Nordisk Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
- 11.4.5 Novo Nordisk Recent Developments
- 11.5 Roche
- 11.5.1 Roche Company Details
- 11.5.2 Roche Business Overview
- 11.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Introduction
- 11.5.4 Roche Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
- 11.5.5 Roche Recent Developments
- 11.6 Vivus
- 11.6.1 Vivus Company Details
- 11.6.2 Vivus Business Overview
- 11.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Introduction
- 11.6.4 Vivus Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
- 11.6.5 Vivus Recent Developments
- 11.7 Arisaph Pharmaceuticals
- 11.7.1 Arisaph Pharmaceuticals Company Details
- 11.7.2 Arisaph Pharmaceuticals Business Overview
- 11.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
- 11.7.4 Arisaph Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
- 11.7.5 Arisaph Pharmaceuticals Recent Developments
- 11.8 Cempra Pharmaceuticals
- 11.8.1 Cempra Pharmaceuticals Company Details
- 11.8.2 Cempra Pharmaceuticals Business Overview
- 11.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
- 11.8.4 Cempra Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
- 11.8.5 Cempra Pharmaceuticals Recent Developments
- 11.9 Galectin Therapeutics
- 11.9.1 Galectin Therapeutics Company Details
- 11.9.2 Galectin Therapeutics Business Overview
- 11.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Introduction
- 11.9.4 Galectin Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
- 11.9.5 Galectin Therapeutics Recent Developments
- 11.10 Galmed Pharmaceuticals
- 11.10.1 Galmed Pharmaceuticals Company Details
- 11.10.2 Galmed Pharmaceuticals Business Overview
- 11.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
- 11.10.4 Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
- 11.10.5 Galmed Pharmaceuticals Recent Developments
- 11.11 Genfit
- 11.11.1 Genfit Company Details
- 11.11.2 Genfit Business Overview
- 11.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Introduction
- 11.11.4 Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
- 11.11.5 Genfit Recent Developments
- 11.12 Gilead
- 11.12.1 Gilead Company Details
- 11.12.2 Gilead Business Overview
- 11.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Introduction
- 11.12.4 Gilead Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
- 11.12.5 Gilead Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
- 13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
- 13.2 Author Details
- 13.3 Disclaimer